Surveillance and Monitoring of Adult Cancer Survivors

Choi, Minsig; Craft, Barbara S.; Geraci, Stephen A.

doi:10.1016/j.amjmed.2010.07.031

Cited by 33 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, some teams allow transplantation of frozen-thawed ovarian tissue from patients with early-stage breast cancer [2,23,33,37]. However, while most breast cancer recurrences manifest within 10 years of the initial diagnosis, the disease can recur much later, emphasizing the need for long-term surveillance in clinical follow-up of these patients [7].…”

Section: Discussionmentioning

confidence: 99%

Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study

Luyckx

Durant

Camboni

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study

Luyckx

Durant

Camboni

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

“…Today, 70% of patients with cancer are expected to survive 5 years from their diagnosis, resulting in an estimated twelve million such cancer survivors living in the USA in 2011 [10,11]. Previous research has shown that men with a history of cancer are 22% more likely to be screened for prostate cancer [12] and that men with a history of cancer had a higher risk of being diagnosed with prostate cancer (standardised incidence ratio 1.3, 95% CI 1.2-1.3) [3].…”

Section: Discussionmentioning

confidence: 99%

“…Using the first cohort, we calculated the ratio of per cent prostate cancer death to per cent prior malignancy death for those with low grade and stage (cT1-2/N0/M0) and high grade (Gleason score [8][9][10] (Fig. 2).…”

Section: Identifying Patients More Likely To Die From Prostate Cancermentioning

confidence: 99%

Risk of prostate cancer mortality in men with a history of prior cancer

et al. 2015

View full text Add to dashboard Cite

ObjectivesTo describe outcomes of patients with prostate cancer diagnosed after another malignancy and identify factors associated with prostate cancer death in this population, as little is known about the clinical significance of prostate cancer as a subsequent malignancy. Patients and MethodsWe studied 18 225 men diagnosed with prostate cancer after another malignancy from 1973 to 2006. We compared demographic and clinical variables, and the proportion of death from prostate cancer vs prior malignancy with t-test and chi-squared analyses. Fine and Gray's regression was used to consider the effect of treatment on prostate cancer death. We then studied a second cohort of 88 013 men with prostate cancer as a first or second malignancy to describe current diagnostic and treatment patterns. ResultsOne in seven men died from prostate cancer in our first cohort. More died from prostate cancer following colorectal cancer (16.8% vs 13.7%), melanoma (13.4% vs 7.56%), and oral cancer (19.1% vs 4.04%), but fewer following bladder cancer, kidney cancer, lung cancer, leukaemia and nonHodgkin's lymphoma (all P < 0.001). Prostate cancer treatment was associated with a nearly 50% lower risk of death when high-grade or high-stage (adjusted hazard ratio 0.55, 95% confidence interval [CI] 0.47-0.64). Patients who died from prostate cancer had higher grade and stage disease, and received less treatment than patients who died from prior malignancy. The second cohort showed subsequent prostate cancer had more high-risk disease (36.3% vs 22.2%, P < 0.001) and less prostate cancer treatment (adjusted odds ratio 0.872, 95% CI 0.818-0.930) than primary prostate cancer. ConclusionsProstate cancer remains a significant cause of mortality when diagnosed as a subsequent cancer. These results suggest prostate cancer treatment should be seriously considered in patients with prior malignancies, especially those with highgrade or locally advanced prostate cancer.

show abstract

“…Bei einigen Erkrankungen ist zwar durchaus von einer verkürzten Lebenserwartung auszugehen, dennoch verbleibt ab der Diagnose (wie beispielsweise Diabetes [1]) voraussichtlich noch eine lange Überlebenszeit. Selbst bei Patienten mit Krebserkrankungen wird davon ausgegangen, dass nach der Diagnose circa 70% von ihnen fünf Jahre und länger überleben [2]. Nun ist bei der Betrachtung von Langzeitüberlebenden nicht nur die Frage nach der Überlebensspan-ne wichtig, sondern auch die Frage, in welcher körperlichen und geistigen Verfassung sie sich befinden [3], an welchen relevanten Lebensbereichen sie teilhaben können und in welchen Bereichen dieses nicht wie gewohnt möglich ist.…”

Section: Die Internationale Klassifikation Der Funktionsfähigkeit Beunclassified

Die Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF) als Klassifikationshilfe der langfristigen Krankheitsfolgen

Ewert

2012

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Surveillance and Monitoring of Adult Cancer Survivors

Cited by 33 publications

References 9 publications

Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study

Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study

Risk of prostate cancer mortality in men with a history of prior cancer

Die Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF) als Klassifikationshilfe der langfristigen Krankheitsfolgen

Contact Info

Product

Resources

About